Patents by Inventor Kevin S. Currie

Kevin S. Currie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
    Publication number: 20030212073
    Abstract: A novel composition comprises a compound of Formula 1 1
    Type: Application
    Filed: April 21, 2003
    Publication date: November 13, 2003
    Inventors: Kevin S. Currie, Robert W. DeSimone, Douglas A. Pippin, James W. Darrow, Scott A. Mitchell
  • Benzimidazole and pyridylimidazole derivatives
    Publication number: 20030069257
    Abstract: This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I 1
    Type: Application
    Filed: December 21, 2001
    Publication date: April 10, 2003
    Inventors: Guiying Li, John M. Peterson, Pamela Albaugh, Kevin S. Currie, Guolin Cai, Linda M. Gustavson, Kyungae Lee, Alan Hutchison, Vinod Singh, George D. Maynard, Jun Yuan, Ling Hong Xie, Manuka Ghosh, Nian Liu, George P. Luke, Scott Mitchell, Martin Patrick Allen, Spiros Liras
  • 2-amino-9-alkylpurines: GABA brain receptor ligands
    Patent number: 6414147
    Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable non-toxic salts thereof wherein: W is oxygen or sulfur; X is (un)substituted lower alkyl; or X is (un)substituted aryl or heteroaryl; Y is hydrogen or lower alkyl; Z is lower alkenyl, lower alkynyl, or (un)substituted lower alkyl; T is (un)substituted aryl or heteroaryl. The compounds are highly selective agonists, antagonists, or inverse agonists for GABAa brain receptors, or prodrugs of agonists, antagonists, or inverse agonists for GABAa brain receptors. Thus these compounds are useful in the diagnosis and treatment of anxiety, sleep and seizure disorders, Down's Syndrome, overdose with benzodiazepine drugs, and for the enhancement of memory.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: July 2, 2002
    Assignee: Neurogen Corporation
    Inventors: Kevin S. Currie, Pamela Albaugh, Paul Chen
  • Substituted 4-oxo-quinoline-3-carboxamides
    Patent number: 6413956
    Abstract: Disclosed are compounds of Formula I: or the pharmaceutically acceptable salts thereof where, R1, R2, and W are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: July 2, 2002
    Assignee: Neurogen Corporation
    Inventors: Pamela A. Albaugh, Kevin S. Currie, Dan Rosewater, Guolin Cai